Is Ultima Genomics profitable in 2026?

Ultima Genomics is private and does not disclose audited financials. CEO Gilad Almogy said at the January 2026 JPMorgan Healthcare Conference that the company doubled its installed base in 2025 and entered 2026 with a contracted revenue backlog, but no profit or verified revenue figure has been published.

Has Ultima Genomics raised a Series B or C round?

No named Series B or C round has been publicly reported as of mid-2026. Ultima's last disclosed raise was $600 million in May 2022 from General Atlantic, a16z, Khosla and others; the company's own site claims over $700 million raised to date, but trackers still show $600M total.

Who are Ultima Genomics' biggest competitors?

Ultima's closest rivals in high-throughput sequencing are Illumina (NovaSeq X), Element Biosciences (Vitari, launched February 2026 at sub-$1M pricing with $175M Samsung backing in June 2026), Roche's forthcoming Axelios, MGI, and PacBio, all targeting the same ultra-high-throughput clinical niche in 2026.

Could AI replace Ultima Genomics?

No. Ultima's core business is physical wet-lab DNA sequencing hardware and chemistry, which generative AI cannot directly replace. Downstream bioinformatics and variant calling, historically handled via Sentieon and Google DeepVariant partnerships, are more exposed to AI commoditization than the sequencing hardware itself.

Who owns Ultima Genomics?

Ultima Genomics is a privately held, venture-backed company founded in 2016 by Gilad Almogy, former head of the display group at Applied Materials. Investors from its $600 million 2022 round include General Atlantic, Andreessen Horowitz, Khosla Ventures, Lightspeed, Founders Fund, and aMoon Fund; Almogy remains CEO.

What does the UG200 sequencer cost and when did it launch?

Ultima launched the UG200 Series in February 2026, priced from $850,000 for the UG200 to $1.25 million for the UG200 Ultra, alongside the new Solaris 2.0 chemistry workflow. Shipments began in Q2 2026, and existing UG100 customers can upgrade in-field to UG100 Plus.

Biotech tools companies · United States

Ultima Genomics

ultimagenomics.com ↗

Startup making high-throughput, low-cost DNA sequencers (UG100/UG200) to challenge Illumina's grip on genomic data.

Losing its protection

Assessed 24 July 2026 · Evidence as of 24 July 2026

The structural protection is eroding.

On the recordSince 24 July 2026 · Checkable from H2 2026 · Every call on the record Checkpoint: Element Biosciences' Vitari sequencer ramps commercial shipments against Ultima's UG200 backlog

The call

Ultima has real machines in real labs, but no new funding round in four years and three well-funded rivals launching cheaper or bigger competing sequencers in the same year.

Ultima Genomics builds machines that read DNA sequences and has sold working hardware to hospitals and research labs, which lock customers into buying their supplies over time. The main threat is Element Biosciences, a competitor backed by Samsung, just released a cheaper machine (Vitari) that costs less than $1 million, while Illumina, the market leader, has shown it will cut prices aggressively to keep customers from switching. Ultima's ability to survive depends on whether its current customers stick with the machines they already own and whether the company can raise money and deliver promised improvements like faster, better data before Element gains too much ground.

Why

AI pressure: None apparent. AI models need more genomic data to train on, so AI drives sequencing demand rather than replacing sequencing hardware. Could AI do the core job? Unlikely.

Bigger players: Illumina (NovaSeq X) and Roche (Axelios, imminent launch). Illumina already cut NovaSeq X prices to defend its low-cost segment, and Roche's Axelios sequencer is set to enter the same price band. Could a giant copy it? Probably.

What protects it. Consumable lock-in from installed UG100/UG200 units plus lab partnerships with Exact Sciences, Labcorp, and NeoGenomics that keep switching costly.

What would change this call

Element Biosciences reports Vitari unit shipments or installed base for H2 2026. Shows whether Element is out-pacing UG200 in the low-cost segment.
Ultima announces a new priced funding round (Series B/C) or discloses valuation. Shows whether investors still back Ultima's growth story after four years without one.
Roche announces Axelios commercial launch date and pricing. Shows whether a third major low-cost entrant intensifies price competition against Ultima.

Key numbers

Installed base of sequencers doubled in 2025, per CEO (2026-01-13)
UG200 series priced $850K to $1.25M, undercutting old UG100 (2026-02-23)
Headcount at 309, down slightly from 2024 peak of 324 (2026-07-10)

Named risks

No named Series B or C funding round in over four years despite intensifying competition. Severity: high
Crowded 2026 launch window with Element Vitari, Roche Axelios, PacBio all targeting same niche. Severity: high
NIH and academic research funding softness pressuring capital equipment sales sector-wide. Severity: medium
Revenue figures undisclosed and third-party estimates inconsistent or unreliable. Severity: medium
Flat to slightly declining headcount despite claimed installed-base doubling. Severity: low

Rivals, as read in July 2026

Rival	Direction	Evidence
Illumina	contesting	NovaSeq X used to defend low-cost segment against Ultima, as of 2026
Element Biosciences	losing to	Vitari launched Feb 2026 at sub-$1M with $175M Samsung backing June 2026
Roche	gaining on	Axelios platform imminent, partnered with 10x Genomics as of March 2026
PacBio	contesting	Developing own high-throughput platform targeting ~10,000 genomes/year, May 2026

Questions people ask

Is Ultima Genomics profitable in 2026?: Ultima Genomics is private and does not disclose audited financials. CEO Gilad Almogy said at the January 2026 JPMorgan Healthcare Conference that the company doubled its installed base in 2025 and entered 2026 with a contracted revenue backlog, but no profit or verified revenue figure has been published.
Has Ultima Genomics raised a Series B or C round?: No named Series B or C round has been publicly reported as of mid-2026. Ultima's last disclosed raise was $600 million in May 2022 from General Atlantic, a16z, Khosla and others; the company's own site claims over $700 million raised to date, but trackers still show $600M total.
Who are Ultima Genomics' biggest competitors?: Ultima's closest rivals in high-throughput sequencing are Illumina (NovaSeq X), Element Biosciences (Vitari, launched February 2026 at sub-$1M pricing with $175M Samsung backing in June 2026), Roche's forthcoming Axelios, MGI, and PacBio, all targeting the same ultra-high-throughput clinical niche in 2026.
Could AI replace Ultima Genomics?: No. Ultima's core business is physical wet-lab DNA sequencing hardware and chemistry, which generative AI cannot directly replace. Downstream bioinformatics and variant calling, historically handled via Sentieon and Google DeepVariant partnerships, are more exposed to AI commoditization than the sequencing hardware itself.
Who owns Ultima Genomics?: Ultima Genomics is a privately held, venture-backed company founded in 2016 by Gilad Almogy, former head of the display group at Applied Materials. Investors from its $600 million 2022 round include General Atlantic, Andreessen Horowitz, Khosla Ventures, Lightspeed, Founders Fund, and aMoon Fund; Almogy remains CEO.
What does the UG200 sequencer cost and when did it launch?: Ultima launched the UG200 Series in February 2026, priced from $850,000 for the UG200 to $1.25 million for the UG200 Ultra, alongside the new Solaris 2.0 chemistry workflow. Shipments began in Q2 2026, and existing UG100 customers can upgrade in-field to UG100 Plus.

Timeline

2026-06-09Element Biosciences raises upsized Series E including $175M from Samsung Electronics
2026-05-08PacBio narrows 2026 guidance citing soft instrument demand
2026-03-19Basecamp Research selects UG200 Series for Trillion Gene Atlas BioAI initiative
2026-03-03GenomeWeb AGBT coverage frames 2026 high-throughput sequencing market as battle royale
2026-02-23Ultima launches UG200 and UG200 Ultra with Solaris 2.0 workflow, priced $850K to $1.25M
2026-02-19Element Biosciences unveils Vitari high-throughput platform at sub-$1M pricing
2026-02-11Ultima adds VP of Oncology Solutions to strengthen clinical leadership
2026-01-13CEO Almogy says Ultima doubled installed base in 2025, entered 2026 with revenue backlog
2024-05-02Former Thermo Fisher COO Mark Stevenson joins Ultima board of directors
2022-05-31Ultima emerges from stealth with $600 million funding and UG100 sequencer claim

Revision history

24 July 2026

First assessed. Losing its protection. The text above is fixed as of this date and is not edited afterwards.

In the same band

Element Biosciences Charles River Laboratories Bio-Techne Corporation